ArticlePharmaceutical biology2022

Gypenosides counteract hepatic steatosis and intestinal barrier injury in rats with metabolic associated fatty liver disease by modulating the adenosine monophosphate activated protein kinase and Toll-like receptor 4/nuclear factor kappa B pathways.

Shuhua Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.